-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Novocure today announced that it has reached a clinical trial collaboration with Roche, combining Tumor Treating Fields (TTFields) with the anti-PD-L1 antibody Tecentriq for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
PDAC is the most common pancreatic cancer, accounting for 85%-95% of all solid pancreatic tumors
When cancer develops, cancerous cells divide rapidly and uncontrollably, and the charged proteins in the cells make the cells susceptible to electric field interference
▲The mechanism of tumor electric field therapy (picture source: Novocure official website)
A few days ago, it has been granted a breakthrough medical device designation by the US FDA.
In September 2018, China Zai Lab obtained the exclusive authorization from Novocure to be responsible for the development and promotion of this technology in Greater China
This phase 2 clinical trial will test the efficacy and safety of the combination of electric field therapy with Tecentriq, gemcitabine, and albumin-bound paclitaxel in the first-line treatment of PDAC patients.
Reference materials:
[1] Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer.
(The original text has been deleted)
